| Applications: | ELISA, WB, ICC/IF |
| Species Reactivity: | Human |
| Isotype: | Mouse IgG1 kappa |
| Immunogen: | Recombinant human EPM2A (243-331aa) purified from E. coli |
| Purification: | By protein-G affinity chromatography |
| Conjugation: | Unconjugated |
| Description: | Epilepsy, progressive myoclonus type 2A (EPM2A), also known as laforin, is a dual-specificity phosphatase that associates with polyribosomes. The protein may be involved in the control of glycogen metabolism, particularly in monitoring for and preventing the formation of poorly branched glycogen molecules. Defects in EPM2A are a cause of progressive myoclonic epilepsy type 2 (EPM2), also known as Lafora disease. EPM2 is an autosomal recessive and severe form of adolescent-onset progressive epilepsy. |
| Further Information: | The antibody has been tested by ELISA and Western blot analysis to assure specificity and reactivity. Since application varies, however, each investigation should be titrated by the reagent to obtain optimal results. Recommended dilution range for Western blot analysis is 1:1,000 ~ 2,000. Recommended starting dilution is 1:1,000. |
| Synonym: | Laforin isoform a,epilepsy, progressive myoclonus type 2A Lafora disease (laforin), epilepsy progressive myoclonus type 2 Lafora disease (laforin), LDE, LD |
| Ascension Number: | O95278 |
| NCBI EntrezGene: | NP_005661 |
| Shipping Conditions: | Ship on cold packs |
| Storage: | Can be stored at +2C to +8C for 1 week. For long term storage, aliquot and store at -20C to -80C. Avoid repeated freezing and thawing cycles. |
| Usage: | Research use only |
